[Clinical evaluation of landiolol hydrochloride, an ultra short-acting beta-blocker].
Postoperative supraventricular tachyarrhythmia (SVT) remains the most common complication of cardiovascular surgery. Current guidelines recommend treatment with beta-blockers in prevention and management of postoperative atrial fibrillation after cardiac surgery. Landiolol hydrochloride is a newly developed ultra short-acting selective beta1-blocker with a half-life of approximately 4 minutes. We investigated its effects on the cardiac function as well as on postoperative SVT. Landiolol hydrochloride had a sufficient therapeutic effect without apparent side effect. After its administration cardiac index decreased, whereas stroke volume increased. Pulmonary artery wedge pressure, pulmonary artery pressure, and central venous pressure remained unchanged. Its main effect proved to be decrease in heart rate.
Tanaka
S
S
Department of Cardiovascular Surgery, Tachikawa Medical Center, Nagaoka, Japan.
Kikuchi
C
C
Saito
N
N
Kasuya
S
S
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D013617:Tachycardia, Supraventricular / Q000188:drug therapy*; D014508:Urea / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D009025:Morpholines; C077049:landiolol; D014508:Urea